PLCε knockdown overcomes drug resistance to androgen receptor antagonist in castration‐resistant prostate cancer by suppressing the wnt3a/β‐catenin pathway
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Cellular Physiology"
DOI: 10.1002/jcp.28195
Abstract: Most prostate cancers (Pcas) develop into castration‐resistant prostate cancer (CRPC) after receiving androgen deprivation therapy (ADT). The expression levels of PLCε and wnt3a are increased in Pca and regulate androgen receptor (AR) activity. However, the… read more here.
Keywords: prostate; wnt3a catenin; drug; resistance ... See more keywords
PLCε knockdown enhances the radiosensitivity of castration-resistant prostate cancer via the AR/PARP1/DNA-PKcs axis
Sign Up to like & getrecommendations! Published in 2020 at "Oncology Reports"
DOI: 10.3892/or.2020.7520
Abstract: Radiotherapy (RT) has been used as a therapeutic option for treatment of prostate cancer (PCa) for a number of years; however, patients frequently develop RT resistance, particularly in castration-resistant PCa (CRPC), although the underlying mechanisms… read more here.
Keywords: parp1; plc knockdown; dna pkcs;